Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00320814 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Study of VEGF Trap in Patients With Diabetic Macular Edema
A Phase 1 study, sponsored by Regeneron Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT00320814: Completed Phase 1 study, sponsored by Regeneron Pharmaceuticals.
NCT00320814 is a Phase 1 study that has completed, run by Regeneron Pharmaceuticals. The registered enrollment target is 5 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00320814, a Phase 1 study, has completed, sponsored by Regeneron Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
To assess the ocular and systemic safety and tolerability of a single intravitreal injection of VEGF Trap in patients with diabetic macular edema.
Interventions
- DRUG VEGF Trap-Eye
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2006-04 |
| Est. Completion | 2007-08 |
| Phase | Phase 1 |
What the finished NCT00320814 record still lists
NCT00320814 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 1 intervention - of which VEGF Trap-Eye is the first listed.
NCT00320814 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00320814 about?
NCT00320814 is a clinical study titled "Phase 1 Study of VEGF Trap in Patients With Diabetic Macular Edema". To assess the ocular and systemic safety and tolerability of a single intravitreal injection of VEGF Trap in patients with diabetic macular edema.
What is the current status of trial NCT00320814?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2006-04. Estimated completion is 2007-08.
What interventions are being tested in trial NCT00320814?
The interventions under investigation include: VEGF Trap-Eye (DRUG).
Who is sponsoring clinical trial NCT00320814?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00320814's enrollment target sits among peer trials
5 1989th of 2000 higher than 6 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia